Please try another search
Troy Edward Wilson, a Director at Puma Biotechnology, Inc. (NASDAQ:PBYI), sold 5,000 shares of the company’s common stock on September 14, 2026. The transaction, executed under a prearranged 10b5-1...
Alessandra Cesano, a director at Puma Biotechnology, Inc. (NASDAQ:PBYI), sold 62,150 shares of the company’s common stock on September 14, 2026. The transactions, conducted under a 10b5-1(c) trading...
Puma Biotechnology, Inc. (PBYI) has initiated a Phase II clinical trial, ALISCA-Lung2, evaluating alisertib in combination with paclitaxel for the treatment of patients with advanced small cell lung...
Are you a technical investor? If so, it may be time to consider Puma Biotechnology, Inc. (NYSE:PBYI) for your portfolio. The company just saw its 50 Day Moving Average breakout above its 200 Day...
Puma Biotechnology, Inc. (NYSE:ANIP) and Retrophin, Inc. (NASDAQ:RTRX) , each sporting a Zacks Rank #1 (Strong Buy). ASTRAZENECA PLC (AZN): Free Stock Analysis Report RETROPHIN INC (RTRX): Free...
Puma Biotechnology, Inc. (NYSE:INVA) and Pfizer Inc. (NYSE:PFE) . While Innoviva sports a Zacks Rank #1 (Strong Buy), Pfizer carries a Zacks Rank #2 (Buy). ROCHE HLDG LTD (RHHBY): Free Stock...
Instrument Type
Region
Sector
Industry
Date
Category
Provider